Recent advances in ophthalmic drug delivery

Therapeutic Delivery

Volumn 1, Issue 3, 2010, Pages 435-456

  Kompella, Uday B ^a   Kadam, Rajendra S ^a   Lee, Vincent H L ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALDOSE REDUCTASE INHIBITOR; AZITHROMYCIN; BESIFLOXACIN; BEVACIZUMAB; CONTACT LENS SOLUTION; CORTICOSTEROID; CYCLODEXTRIN; CYCLOSPORIN A; DEXAMETHASONE; DICLOFENAC; DIPIVEFRINE; FLUOCINOLONE ACETONIDE; GANCICLOVIR; GATIFLOXACIN; IMMUNOSUPPRESSIVE AGENT; LATANOPROST; NANOPARTICLE; NORFLOXACIN; PEGAPTANIB; PILOCARPINE; POLYCARBOPHIL; POLYMACON; PRODRUG; PROPRANOLOL; RANIBIZUMAB; TIMOLOL MALEATE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNIL 088; UNINDEXED DRUG;

AREA UNDER THE CURVE; BACTERIAL INFECTION; BIOCOMPATIBILITY; BIODEGRADABLE IMPLANT; BLOOD EYE BARRIER; BLURRED VISION; CATARACT; CLINICAL EFFECTIVENESS; CONJUNCTIVITIS; CORNEA NEOVASCULARIZATION; CORNEA PERMEABILITY; CYTOMEGALOVIRUS RETINITIS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DOSE CALCULATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG HALF LIFE; DRUG IMPLANT; DRUG MECHANISM; DRUG PENETRATION; DRUG RETENTION; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; ENDOPHTHALMITIS; EYE DISCOMFORT; EYE DISEASE; EYE IRRITATION; FEASIBILITY STUDY; GLAUCOMA; GRAFT REJECTION; HUMAN; HYDROGEL; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IONTOPHORESIS; LACRIMATION; LIPOSOMAL DELIVERY; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; MOLECULAR IMPRINTING; MUCOADHESION; NANOPHARMACEUTICS; NONHUMAN; OCULAR PRURITUS; PRIORITY JOURNAL; PROCESS DESIGN; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOFT CONTACT LENS; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; UVEITIS;

EID: 79954520410     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.40     Document Type: Review

References (136)

1. Rein DB, Wittenborn JS, Zhang X, Honeycutt AA, Lesesne SB, Saaddine J. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch. Ophthalmol. 127(4), 533-540 (2009).
2. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol. Rep. 58(3), 353-363 (2006). (Pubitemid 44111070)
3. VisionGain. World ophthalmic pharmaceutical market 2010-2025. Visiongain Reports (2010).
4. Cheruvu NP, Amrite AC, Kompella UB. Effect of diabetes on trans-scleral delivery of celecoxib. Pharm. Res. 26(2), 404-414 (2009).
5. Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol. Vis. 14, 150-160 (2008). (Pubitemid 351194002)
6. Cheruvu NP, Amrite AC, Kompella UB. Effect of eye pigmentation on trans-scleral drug delivery. Invest. Ophthalmol. Vis. Sci. 49(1), 333-341 (2008).
7. Amrite AC, Edelhauser HF, Kompella UB. Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Invest. Ophthalmol. Vis. Sci. 49(1), 320-332 (2008).
8. Kador PF, Randazzo J, Babb T, et al. Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts. J. Ocul. Pharmacol. Ther. 23(2), 116-123 (2007). (Pubitemid 46642153)
9. Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest. Ophthalmol. Vis. Sci. 47(3), 1149-1160 (2006). (Pubitemid 46768351)
10. Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur. J. Pharmacol. 511(2-3), 191-198 (2005). (Pubitemid 40417726)
11. Ayalasomayajula SP, Kompella UB. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared with systemic administration. Pharm. Res. 21(10), 1797-1804 (2004). (Pubitemid 39390091)
12. Koushik K, Kompella UB. Preparation of large porous deslorelin-plga microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process. Pharm. Res. 21(3), 524-535 (2004). (Pubitemid 38338989)
13. Sunkara G, Ayalasomayajula SP, Rao CS, Vennerstrom JL, Deruiter J, Kompella UB. Systemic and ocular pharmacokinetics of N-4- benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor. J. Pharm. Pharmacol. 56(3), 351-358 (2004). (Pubitemid 38380217)
14. Aukunuru JV, Sunkara G, Ayalasomayajula SP, Deruiter J, Clark RC, Kompella UB. A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. Pharm. Res. 19(3), 278-285 (2002). (Pubitemid 34211844)
15. Proksch JW, Granvil CP, Siou-Mermet R, Comstock TL, Paterno MR, Ward KW. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J. Ocul. Pharmacol. Ther. 25(4), 335-344 (2009).
16. Lee VH, Robinson JR. Topical ocular drug delivery: recent developments and future challenges. J. Ocul. Pharmacol. 2(1), 67-108 (1986). (Pubitemid 17193813)
17. Macha S, Mitra AK. Ocular pharmacokinetics in rabbits using a novel dual probe microdialysis technique. Exp. Eye Res. 72(3), 289-299 (2001). (Pubitemid 32977982)
18. Macha S, Duvvuri S, Mitra AK. Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis. Curr. Eye. Res. 28(2), 77-84 (2004). (Pubitemid 38200942)
19. Dias CS, Mitra AK. Posterior segment ocular pharmacokinetics using microdialysis in a conscious rabbit model. Invest. Ophthalmol. Vis. Sci. 44(1), 300-305 (2003). (Pubitemid 36134288)
20. Rittenhouse KD, Peiffer RL Jr, Pollack GM. Evaluation of microdialysis sampling of aqueous humor for in vivo models of ocular absorption and disposition. J. Pharm. Biomed. Anal. 16(6), 951-959 (1998). (Pubitemid 28139032)
21. Pearson PA, Jaffe GJ, Martin DF, et al. Evaluation of a delivery system providing long-term release of cyclosporine. Arch. Ophthalmol. 114(3), 311-317 (1996).
22. Acheampong AA, Shackleton M, Tang-Liu DD, Ding S, Stern ME, Decker R. Distribution of cyclosporin a in ocular tissues after topical administration to albino rabbits and beagle dogs. Curr. Eye Res. 18(2), 91-103 (1999). (Pubitemid 29137565)
23. Wei G, Xu H, Ding PT, Li SM, Zheng JM. Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and g scintigraphic studies. J. Control. Release 83(1), 65-74 (2002). (Pubitemid 35239815)
24. Klyce SD, Crosson CE. Transport processes across the rabbit corneal epithelium: a review. Curr. Eye Res. 4(4), 323-331 (1985). (Pubitemid 15123153)
25. Kompella UB, Kim KJ, Lee VH. Active chloride transport in the pigmented rabbit conjunctiva. Curr. Eye Res. 12(12), 1041-1048 (1993). (Pubitemid 24033639)
26. Wang W, Sasaki H, Chien DS, Lee VH. Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit: a comparison with corneal penetration. Curr. Eye Res. 10(6), 571-579 (1991).
27. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin. Drug Deliv. 1(1), 99-114 (2004). (Pubitemid 40297959)
28. Rao VR, Prescott E, Shelke NB, et al. Delivery of SAR 1118 to retina via ophthalmic drops and its effectiveness in reduction of retinal leukostasis and vascular leakiness in rat streptozotocin (STZ) model of diabetic retinopathy (DR). Invest. Ophthalmol. Vis. Sci. DOI:10.1167/iovs.09-5144 (2010) (Epub ahead of print).
29. Hariprasad SM, Mieler WF, Holz ER. Vitreous and aqueous penetration of orally administered gatifloxacin in humans. Arch. Ophthalmol. 121(3), 345-350 (2003). (Pubitemid 36298116)
30. Olsen TW, Feng X, Wabner K, et al. Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment. Am. J. Ophthalmol. 142(5), 777-787 (2006).
31. Felt O, Furrer P, Mayer JM, Plazonnet B, Buri P, Gurny R. Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention. Int. J. Pharm. 180(2), 185-193 (1999). (Pubitemid 29238202)
32. Meseguer G, Gurny R, Buri P, Rozier A, Plazonnet B. g scintigraphic study of precorneal drainage and assessment of miotic response in rabbits of various ophthalmic formulations containing pilocarpine. Int. J. Pharm. 95, 229-234 (1993). (Pubitemid 23203156)
33. Yamamura K, Sasaki H, Nakashima M, et al. Characterization of ocular pharmacokinetics of b-blockers using a diffusion model after instillation. Pharm. Res. 16(10), 1596-1601 (1999). (Pubitemid 29510558)
34. Akpek EK, Vittitow J, Verhoeven RS, et al. Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. J. Ocul. Pharmacol. Ther. 25(5), 433-439 (2009).
35. Hornof MD, Bernkop-Schnurch A. In vitro evaluation of the permeation enhancing effect of polycarbophil-cysteine conjugates on the cornea of rabbits. J. Pharm. Sci. 91(12), 2588-2592 (2002). (Pubitemid 35385624)
36. Maurice D. The effect of the low blink rate in rabbits on topical drug penetration. J. Ocul. Pharmacol. Ther. 11(3), 297-304 (1995).
37. Witcherle O, Lim D. Hydrophilic gels for biological use. Nature 185, 117-118 (1960).
38. Lim L, Loughnan MS, Sullivan LJ. Microbial keratitis associated with extended wear of silicone hydrogel contact lenses. Br. J. Ophthalmol. 86(3), 355-357 (2002). (Pubitemid 34207786)
39. Hehl EM, Beck R, Luthard K, Guthoff R, Drewelow B. Improved penetration of aminoglycosides and fluorozuinolones into the aqueous humour of patients by means of acuvue contact lenses. Eur. J. Clin. Pharmacol. 55(4), 317-323 (1999). (Pubitemid 29290925)
40. Sedlacek J. Possibility of the application of ophthalmic drugs with the use of gel contact lenses. Cesk. Oftalmol. 21(6), 509-512 (1965).
41. Karlgard CC, Jones LW, Moresoli C. Ciprofloxacin interaction with silicon-based and conventional hydrogel contact lenses. Eye Contact Lens 29(2), 83-89 (2003). (Pubitemid 43189073)
42. Karlgard CC, Wong NS, Jones LW, Moresoli C. In vitro uptake and release studies of ocular pharmaceutical agents by silicon-containing and p-HEMA hydrogel contact lens materials. Int. J. Pharm. 257(1-2), 141-151 (2003). (Pubitemid 36507040)
43. Kim J, Conway A, Chauhan A. Extended delivery of ophthalmic drugs by silicone hydrogel contact lenses. Biomaterials 29(14), 2259-2269 (2008).
44. Haugen B, Werner L, Romaniv N, et al. Prevention of endophthalmitis by collagen shields presoaked in fourth-generation fluoroquinolones versus by topical prophylaxis. J. Cataract Refract. Surg. 34(5), 853-858 (2008). (Pubitemid 351615502)
45. Hiratani H, Alvarez-Lorenzo C. Timolol uptake and release by imprinted soft contact lenses made of N,N-diethylacrylamide and methacrylic acid. J. Control. Release 83(2), 223-230 (2002). (Pubitemid 35279467)
46. Alvarez-Lorenzo C, Yanez F, Barreiro-Iglesias R, Concheiro A. Imprinted soft contact lenses as norfloxacin delivery systems. J. Control. Release 113(3), 236-244 (2006). (Pubitemid 43963192)
47. Ali M, Horikawa S, Venkatesh S, Saha J, Hong JW, Byrne ME. Zero-order therapeutic release from imprinted hydrogel contact lenses within in vitro physiological ocular tear flow. J. Control. Release 124(3), 154-162 (2007). (Pubitemid 350110488)
48. Danion A, Brochu H, Martin Y, Vermette P. Fabrication and characterization of contact lenses bearing surface-immobilized layers of intact liposomes. J. Biomed. Mater. Res. A 82(1), 41-51 (2007). (Pubitemid 46906490)
49. Danion A, Arsenault I, Vermette P. Antibacterial activity of contact lenses bearing surface-immobilized layers of intact liposomes loaded with levofloxacin. J. Pharm. Sci. 96(9), 2350-2363 (2007). (Pubitemid 47477891)
50. Ciolino JB, Hoare TR, Iwata NG, et al. A drug-eluting contact lens. Invest. Ophthalmol. Vis. Sci. 50(7), 3346-3352 (2009).
51. Sano K, Tokoro T, Imai Y. A new drug delivery system utilizing piggyback contact lenses. Acta. Ophthalmol. Scand. 74(3), 243-248 (1996). (Pubitemid 26229722)
52. Gulsen D, Chauhan A. Dispersion of microemulsion drops in HEMA hydrogel: a potential ophthalmic drug delivery vehicle. Int. J. Pharm. 292(1-2), 95-117 (2005). (Pubitemid 40255792)
53. Gulsen D, Li CC, Chauhan A. Dispersion of DMPC liposomes in contact lenses for ophthalmic drug delivery. Curr. Eye Res. 30(12), 1071-1080 (2005). (Pubitemid 41798067)
54. Gulsen D, Chauhan A. Ophthalmic drug delivery through contact lenses. Invest. Ophthalmol. Vis. Sci. 45(7), 2342-2347 (2004). (Pubitemid 38902607)
55. Kapoor Y, Thomas JC, Tan G, John VT, Chauhan A. Surfactant-laden soft contact lenses for extended delivery of ophthalmic drugs. Biomaterials 30(5), 867-878 (2009).
56. Lim M, Jacobs DS, Rosenthal P, Carrasquillo KG. The boston ocular surface prosthesis as a novel drug delivery system for bevacizumab. Seminars in Ophthalmology 24(3), 149-155 (2009).
57. Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 115(6), e33-38 (2008).
58. Ottiger M, Thiel MA, Feige U, Lichtlen P, Urech DM. Efficient intraocular penetration of topical anti-TNF-asingle-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest. Ophthalmol. Vis. Sci. 50(2), 779-786 (2009).
59. Calonge M. The treatment of dry eye. Surv. Ophthalmol. 45(Suppl. 2), S227-S239 (2001).
60. Balaram M, Schaumberg DA, Dana MR. Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome. Am. J. Ophthalmol. 131(1), 30-36 (2001). (Pubitemid 32037005)
61. Wei CP, Anderson JA, Leopold I. Ocular absorption and metabolism of topically applied epinephrine and a dipivalyl ester of epinephrine. Invest. Ophthalmol. Vis. Sci. 17(4), 315-321 (1978). (Pubitemid 8301749)
62. Kass MA, Mandell AI, Goldberg I, Paine JM, Becker B. Dipivefrin and epinephrine treatment of elevated intraocular pressure: a comparative study. Arch. Ophthalmol. 97(10), 1865-1866 (1979). (Pubitemid 9253660)
63. Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 7(3), 255-270 (2008). (Pubitemid 351324639)
64. Hellberg MR, Ke TL, Haggard K, Klimko PG, Dean TR, Graff G. The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF2aby human and rabbit ocular tissue. J. Ocul. Pharmacol. Ther. 19(2), 97-103 (2003). (Pubitemid 36539135)
65. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 132(4), 472-484 (2001). (Pubitemid 32904567)
66. Susanna R Jr, Chew P, Kitazawa Y. Current status of prostaglandin therapy: latanoprost and unoprostone. Surv. Ophthalmol. 47(Suppl. 1), S97-S104 (2002). (Pubitemid 35232223)
67. Lallemand F, Perottet P, Felt-Baeyens O, et al. A water-soluble prodrug of cyclosporine a for ocular application: a stability study. Eur. J. Pharm. Sci. 26(1), 124-129 (2005). (Pubitemid 41097269)
68. Lallemand F, Felt-Baeyens O, Rudaz S, et al. Conversion of cyclosporine a prodrugs in human tears vs rabbits tears. Eur. J. Pharm. Biopharm. 59(1), 51-56 (2005). (Pubitemid 39573436)
69. Liu H, Wang Y, Li S. Advanced delivery of ciclosporin a: present state and perspective. Expert Opin. Drug Deliv. 4(4), 349-358 (2007). (Pubitemid 47249136)
70. Olivero DK, Davidson MG, English RV, Nasisse MP, Jamieson VE, Gerig TM. Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs. J. Am. Vet. Med. Assoc. 199(8), 1039-1042 (1991).
71. Benitez Del Castillo JM, Del Aguila C, Duran S, Hernandez J, Garcia Sanchez J. Influence of topically applied cyclosporine a in olive oil on corneal epithelium permeability. Cornea 13(2), 136-140 (1994). (Pubitemid 24083050)
72. Bourges JL, Lallemand F, Agla E, et al. Evaluation of a topical cyclosporine a prodrug on corneal graft rejection in rats. Mol. Vis. 12, 1461-1466 (2006). (Pubitemid 46117008)
73. Dey S, Anand BS, Patel J, Mitra AK. Transporters/receptors in the anterior chamber: pathways to explore ocular drug delivery strategies. Expert Opin. Biol. Ther. 3(1), 23-44 (2003). (Pubitemid 36193649)
74. Janoria KG, Gunda S, Boddu SH, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin. Drug Deliv. 4(4), 371-388 (2007). (Pubitemid 47260195)
75. Hosoya K, Tachikawa M. Inner blood-retinal barrier transporters: role of retinal drug delivery. Pharm. Res. 26(9), 2055-2065 (2009).
76. Ueda H, Horibe Y, Kim KJ, Lee VH. Functional characterization of organic cation drug transport in the pigmented rabbit conjunctiva. Invest. Ophthalmol. Vis. Sci. 41(3), 870-876 (2000). (Pubitemid 30158901)
77. Karla PK, Pal D, Mitra AK. Molecular evidence and functional expression of multidrug resistance associated protein (MRP) in rabbit corneal epithelial cells. Exp. Eye Res. 84(1), 53-60 (2007). (Pubitemid 44792052)
78. Mannermaa E, Vellonen KS, Ryhanen T, et al. Efflux protein expression in human retinal pigment epithelium cell lines. Pharm. Res. 26(7), 1785-1791 (2009).
79. Prasanna G, Fortner J, Xiang C, et al. Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models. Exp. Eye Res. 89(5), 608-617 (2009).
80. Gehlbach P, Demetriades AM, Yamamoto S, et al. Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization. Gene Ther. 10(8), 637-646 (2003). (Pubitemid 36553609)
81. Kompella UB, Sundaram S, Raghava S, Escobar ER. Luteinizing hormone-releasing hormone agonist and transferrin functionalizations enhance nanoparticle delivery in a novel bovine ex vivo eye model. Mol. Vis. 12, 1185-1198 (2006).
82. Loftssona T, Jarvinen T. Cyclodextrins in ophthalmic drug delivery. Adv. Drug Deliv. Rev. 36(1), 59-79 (1999). (Pubitemid 29074477)
83. Stefansson E, Loftssona T. Cyclodextrins in eye drop formulations. J. Incl. Phenomena Macrocyclic Chem. 44, 23-27 (2002). (Pubitemid 38075658)
84. Bary AR, Tucker IG, Davies NM. Considerations in the use of hydroxypropyl-b-cyclodextrin in the formulation of aqueous ophthalmic solutions of hydrocortisone. Eur. J. Pharm. Biopharm. 50(2), 237-244 (2000).
85. Loftsson T, Frithriksdottir H, Stefansson E, Thorisdottir S, Guthmundsson O, Sigthorsson T. Topically effective ocular hypotensive acetazolamide and ethoxyzolamide formulations in rabbits. J. Pharm. Pharmacol. 46(6), 503-504 (1994). (Pubitemid 24179546)
86. Cheeks L, Kaswan RL, Green K. Influence of vehicle and anterior chamber protein concentration on cyclosporine penetration through the isolated rabbit cornea. Curr. Eye Res. 11(7), 641-649 (1992).
87. Loftsson T, Fridriksdottir H, Thorisdottir S, Stefansson E. The effect of hydroxypropyl methylcellulose on release of dexamethazone from aqueous 2-hydroxypropyl-b-cyclodextrin formulations. Int. J. Pharm. 104, 181-184 (1994). (Pubitemid 24073703)
88. Kristinsson JK, Fridriksdottir H, Thorisdottir S, Sigurdardottir AM, Stefansson E, Loftsson T. Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans. Invest. Ophthalmol. Vis. Sci. 37(6), 1199-1203 (1996). (Pubitemid 26164250)
89. Ashton P, Podder SK, Lee VH. Formulation influence on conjunctival penetration of four bblockers in the pigmented rabbit: a comparison with corneal penetration. Pharm. Res. 8(9), 1166-1174 (1991).
90. Lee YH, Lee VH. Formulation influence on ocular and systemic absorption of topically applied atenolol in the pigmented rabbit. J. Ocul. Pharmacol. 9(1), 47-58 (1993). (Pubitemid 23100652)
91. Scholz M, Lin JE, Lee VH, Keipert S. Pilocarpine permeability across ocular tissues and cell cultures: influence of formulation parameters. J. Ocul. Pharmacol. Ther. 18(5), 455-468 (2002). (Pubitemid 37420254)
92. Lee VH, Yamamoto A, Kompella UB. Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Crit. Rev. Ther. Drug Carrier Syst. 8(2), 91-192 (1991).
93. Eljarrat-Binstock E, Domb AJ. Iontophoresis: a noninvasive ocular drug delivery. J. Control. Release 110(3), 479-489 (2006). (Pubitemid 43163439)
94. Nurieva SM. [Effect on the eye vessels of vasodilator agents after their administration by different electrophoretic methods (clinical study)]. Vestn. Oftalmol. (2), 71-73 (1978).
95. Polunin GS, Kas'ianova NS. [Fluorophotometry in the clinical aspects of eye diseases]. Vestn. Oftalmol. (5), 52-57 (1979).
96. Bourne WM, Brubaker RF. Decreased endothelial permeability in the iridocorneal endothelial syndrome. Ophthalmology 89(6), 591-595 (1982). (Pubitemid 12085990)
97. Maurice DM. Iontophoresis of fluorescein into the posterior segment of the rabbit eye. Ophthalmology 93(1), 128-132 (1986). (Pubitemid 16132698)
98. Meyer DR, Linberg JV, Vasquez RJ. Iontophoresis for eyelid anesthesia. Ophthalmic Surg 21(12), 845-848 (1990).
99. Horwath-Winter J, Schmut O, Haller-Schober EM, Gruber A, Rieger G. Iodide iontophoresis as a treatment for dry eye syndrome. Br. J. Ophthalmol. 89(1), 40-44 (2005). (Pubitemid 40040236)
100. Parkinson TM, Ferguson E, Febbraro S, Bakhtyari A, King M, Mundasad M. Tolerance of ocular iontophoresis in healthy volunteers. J. Ocul. Pharmacol. Ther. 19(2), 145-151 (2003). (Pubitemid 36539140)
101. Amrite A, Pugazhenthi V, Cheruvu N, Kompella U. Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes. Expert Opin. Drug Deliv. 7(5), 631-645 (2010).
102. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J. Pharm. Sci. 87(12), 1479-1488 (1998).
103. Kim TW, Lindsey JD, Aihara M, Anthony TL, Weinreb RN. Intraocular distribution of 70-kDa dextran after subconjunctival injection in mice. Invest. Ophthalmol. Vis. Sci. 43(6), 1809-1816 (2002). (Pubitemid 34587025)
104. Cheruvu NP, Kompella UB. Bovine and porcine trans-scleral solute transport: influence of lipophilicity and the choroid-bruch's layer. Invest. Ophthalmol. Vis. Sci. 47(10), 4513-4522 (2006). (Pubitemid 46579380)
105. Kadam RS, Kompella UB. Influence of lipophilicity on drug partitioning into sclera, choroid-retinal pigment epithelium, retina, trabecular meshwork, and optic nerve. J. Pharmacol. Exp. Ther. 332(3), 1107-1120 (2010).
106. Durairaj C, Shah JC, Senapati S, Kompella UB. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm. Res. 26(5), 1236-1260 (2009).
107. Durairaj C, Kim SJ, Edelhauser HF, Shah JC, Kompella UB. Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. Invest. Ophthalmol. Vis. Sci. 50(10), 4887-4897 (2009).
108. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20(3), 244-250 (2000). (Pubitemid 30436775)
109. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch. Ophthalmol. 121(1), 57-61 (2003). (Pubitemid 36401766)
110. Jonas JB. Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res. 38(4), 218-245 (2006). (Pubitemid 44213982)
111. Mason JO 3rd, Somaiya MD, Singh RJ. Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes. Retina 24(6), 900-904 (2004). (Pubitemid 39657486)
112. Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina 25(5), 556-560 (2005).
113. Choonara YE, Pillay V, Danckwerts MP, Carmichael TR, Du Toit LC. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases. J. Pharm. Sci. 99(5), 2219-2239 (2009).
114. Short BG. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol. Pathol. 36(1), 49-62 (2008).
115. Bourges JL, Bloquel C, Thomas A, et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv. Drug Deliv. Rev. 58(11), 1182-1202 (2006). (Pubitemid 44794429)
116. Ramchandran RS, Fekrat S, Stinnett SS, Jaffe GJ. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results. Am. J. Ophthalmol. 146(2), 285-291 (2008).
117. Ayalasomayajula SP, Ashton P, Kompella UB. Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial (ARPE-19) cells and TNF-a-induced angiogenesis in chick chorioallantoic membrane (CAM). J. Ocul. Pharmacol. Ther. 25(2), 97-103 (2009).
118. Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov. Today 13(3-4), 135-143 (2008).
119. Kompella UB, Li X, Zhan G, Lee SS. Influence of intravitreal implant location on ocular disposition of fluocinolone acetonide. ARVO Annual Meeting 5971/A5594 (2009).
120. Novack GD. Ophthalmic drug delivery: development and regulatory considerations. Clin. Pharmacol. Ther. 85(5), 539-543 (2009).
121. Rieke ER, Amaral J, Patricia Becerra S, Lutz RJ. Sustained subconjunctival protein delivery using a thermosetting gel delivery system. J. Ocul. Pharmacol. Ther. (2010) (In Press).
122. Kim EY, Gao ZG, Park JS, Li H, Han K. RHEGF/HP-b-CD complex in poloxamer gel for ophthalmic delivery. Int. J. Pharm. 233(1-2), 159-167 (2002). (Pubitemid 34230428)
123. Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano-and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest. Ophthalmol. Vis. Sci. 44(3), 1192-1201 (2003). (Pubitemid 36297840)
124. Kang SJ, Durairaj C, Kompella UB, O'Brien JM, Grossniklaus HE. Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. Arch. Ophthalmol. 127(8), 1043-1047 (2009).
125. Chiang CH, Tung SM, Lu DW, Yeh MK. In vitro and in vivo evaluation of an ocular delivery system of 5-fluorouracil microspheres. J. Ocul. Pharmacol. Ther. 17(6), 545-553 (2001).
126. Van Quill KR, Dioguardi PK, Tong CT, et al. Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology 112(6), 1151-1158 (2005). (Pubitemid 40797475)
127. Saishin Y, Silva RL, Saishin Y, et al. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest. Ophthalmol. Vis. Sci. 44(11), 4989-4993 (2003). (Pubitemid 37315317)
128. Sunkara G, Kompella UB. Membrane transport processes in the eye. In: Ophthalmic Drug Delivery Systems, Mitra AK (Ed.). Marcel Dekker Inc., NY, USA, 13-58 (2003).
129. Bowman LM, Roy S, Pens S. Topical treatment for prevention of ocular infections. WO019366 (2001).
130. Nakada K, Sugiyama A. Process for producing controlled drug-release contact lens, and controlled drug-release contact lens thereby produced. US6027745 (1998).
131. Rosenthal P, Jacobs D. Drug delivery systems with scleral lens. US0286338 (2008).
132. Borgia MJ, Chaouk H, Cui H, Laredo W, Li Z, Nathan A. Punctal plugs for the delivery of active agents. US0045911 (2008).
133. Rodstrom T, Smith L, Tian Y, Marsh D, Weiner A, Bakshi S. Punctal plugs and methods of delivering therapeutic agents. WO094989 (2008)
134. Chauhan A, Hens Z. Dry eye treatment by punctal plug. WO079559 (2009)
135. Punctal plugs and moisture treatment in dry eye treatment -the eye digest www.agingeye.net/dryeyes/plugsetc.php
136. QLT Inc. www.qltinc.com